Clearbridge BioMedics has obtained ISO13485 certification for the development of cell-based in-vitro diagnostic devices.
As part of the certification, the company has also introduced its ClearCell system which helps in isolating circulating tumour cells (CTC) from blood.
ClearCell system, which comprises of the proprietary CTChip, can retrieve viable CTCs in their native states without the use of antibodies or magnetic beads, thus facilitating cancer researchers to better understand the relationship between such cells and mechanisms of cancer.
Clearbridge BioMedics co-founder Johnson Chen said moving forward, the company is working towards the development of the ClearCell system for in-vitro diagnostic applications.
The company said it will exhibit its ClearCell system at the American Association for Cancer Research annual meeting from 31 March to 4 April 2012 in Chicago, US.
In addition to marketing the ClearCell system directly to the research community, Clearbridge has signed a distribution agreement with Abnova for its ClearCell unit and CTChip.